Figure 1 | Scientific Reports

Figure 1

From: Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study

Figure 1

Primary and secondary endpoint results for the monotherapy and combination groups. (A) DAS28, (B) HAQ, (C) ESR, (D) CRP, (E) TJC28, (F) SJC28, (G) MSD, (H) PtGA. DAS28 28-joint disease activity score calculated with C-reactive protein, HAQ health assessment questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, TJC28 tender joint count of 28 joints, SJC28 swollen joint count of 28 joints, MSD morning stiffness duration, PtGA patient global assessment. Data are shown as means ± SEM. *Indicate significant differences between different groups at the same time point (P < 0.05). #Significance as compared with baseline in the monotherapy group (P < 0.05). $Significance as compared with baseline in the combination group ($P < 0.05; $$P < 0.01; $$$P < 0.001).

Back to article page